NCT02733133View on ClinicalTrials.gov

Product Transference Study of Testagen™ TDS®-Testosterone

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Hypogonadotropism
Interventions
DRUG

Testagen® TDS Testosterone 5% HypoSpray®

Topically applied Testosterone Hormone Replacement Lotion

All Listed Sponsors
collaborator

Advanced Therapies Centre, The London Clinic

OTHER

lead

Transdermal Delivery Solutions Corp

INDUSTRY